ArticleMolecular oncology2019

RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.

Erik J van Helden et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.